

---

<b>Product name:</b>	BCL-10 Mouse Monoclonal Antibody
<b>Cat number:</b>	MABN80502
<b>Conjugate:</b>	Unconjugated
<b>Size:</b>	100µL
<b>Clone:</b>	Monoclonal
<b>Concentration:</b>	1mg/ml
<b>Host:</b>	Mouse
<b>Isotype:</b>	Mouse IgG1
<b>Immunogen:</b>	Purified recombinant fragment of human BCL-10 expressed in E. Coli.
<b>Reactivity:</b>	Human,Mouse
<b>Applications:</b>	WB 1:500-1:2000,IHC 1:200-1:1000,ICC 1:200-1:1000,ELISA 1:5000-1:20000,FC 1:200-1:400
<b>Molecular Weight:</b>	26kDa
<b>Purification:</b>	Affinity Purification
<b>Form:</b>	Liquid
<b>Buffer:</b>	Ascitic fluid containing 0.03% sodium azide.
<b>Storage:</b>	Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles.
<b>Background:</b>	<p>Bcl-10 (B-cell CLL/lymphoma 10), also known as CLAP, Me10, CIPER, c-E10, CARMEN. Entrez Protein NP_003912. It is a protein containing a caspase recruitment domain (CARD). It plays an important role in apoptosis and activating NF-kappaB. The research suggested that it interacted with other CARD domain containing proteins including CARD9, 10, 11 and 14, which were thought to function as upstream regulators in NF-kappaB signaling. Bcl-10 is found to form a complex with MALT1 which encoded by another gene known to be translocated in MALT lymphoma. MALT1 and Bcl-10 are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.</p>